whatshot

ACRX   $0.8719  7.50% Market Closed

AcelRx Pharmaceuticals Inc
show_chart Advanced Chart of ACRX
Last Events:

2023-08-06 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-08-03 Trend pattern changed from канал to расширяющийся канал.

2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

Current temperature: 2.35
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 4.63
Mean unverified/preliminary 4.63 / 4.63
Target Price Low / High 4.25 / 5.00
Median / STD DEV 4.63 / 0.53
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy ActivelyBuy
rsi Sell ActivelyBuy Buy
macd ActivelyBuy None None
stoch None None None
ma20 Sell Buy ActivelyBuy
ma50 ActivelyBuy None None
ma100 Sell None ActivelyBuy
Candlestick PatternNov. 13, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US00444T2096
ceo Mr. Vincent J. Angotti
Website https://www.acelrx.com
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.